Kornimate/medical-research-clean huggingface dataset:
formulating expert consensus guidelines in cancer care using the delphi method

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust delphi technique, completely remote and electronic. the goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. these recommendations would be used to develop standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivorship.

primary objective: i. to formulate consensus agreement on a minimum set of clinical key elements that should be included in standardized reports in electronic health records when managing patients with prostate cancer. outline: participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.

Eligibility criteria:
inclusion criteria: * age 21 and above * board certification in radiation oncology, radiation physics, urology, and/or medical oncology * maintenance of an active practice that includes prostate cancer patients * english speaking exclusion criteria: * medical providers that are not board certified in the professions and/or those who do not treat prostate cancer * prisoners, children, and adults unable to consent to participation will also be excluded * no exclusions were made based on sex, age, racial/ethnic background, or pregnancy status
clinical study of a uv-absorbing acrylic posterior chamber intraocular lens

Conditions: Aphakia

Summary: the purpose of this study is to assess the safety and efficacy of the hmy model ya-60bb intraocular lens (iol) when implanted in the posterior chamber of the human eye for the optical correction of aphakia following cataract extraction.

a prospective, single-phase, non-randomized, open-label study to include patients with operable cataract of the human crystalline lens who have a potential post-operative best corrected visual acuity of 20/40 or better and no pre-existing progressive sight-threatening ocular disorders. patients who are eligible per inclusion / exclusion criteria will undergo phacoemulsification cataract extraction and then implantation of the hoya hmy model ya-60bb posterior chamber intraocular lens. each patient will be followed-up at specific time intervals to assess safety and effectiveness, for up to 36 months.

Eligibility criteria:
inclusion criteria: 1. adult patients with cataract who are eligible for phacoemulsification cataract extraction of the lens through an incision of approximately 4 mm, and primary implantation of a posterior chamber intraocular lens. 2. patients must have no pre-existing ocular conditions that preclude the ability of the treated eye to achieve bcva of 20/40 or better after iol implantation. 3. patients must be at least 21 years of age. 4. patients must sign a written informed consent form. 5. patients must be able and willing to return for scheduled follow-up examinations after surgery throughout the 36 month study. exclusion criteria: 1. patients with a history of/or clinical signs of any of the following sight-threatening conditions: 1. previous retinal detachment or retinal pathology in operative eye, only 2. macular degeneration in either eye 3. macular edema in either eye 4. persistent iritis/uveitis in operative eye, only 2. uncontrolled glaucoma or under current treatment for glaucoma in either eye 3. significant corneal disease in operative eye, only 4. proliferative diabetic retinopathy in either eye 5. patients who have had previous ocular surgery, of any kind, within the last 6 months or patients who have had previous ocular surgery at any time and who do not have potential bcva after cataract extraction/iol implantation of 20/40 or better 6. patients who have best corrected vision worse than 20/200 in the fellow eye. 7. patients with serious (i.e., life threatening) non-ophthalmic disease which may preclude study completion. 8. patients who have undergone previous cataract extraction and intraocular lens implantation. 9. patients unwilling or unable to sign the irb-approved informed consent document for the study or who cannot or will not complete the study's examination schedule. 10. patients who are currently enrolled in another clinical trial, or who exited a clinical trial within the last 30 days.

Keywords: cataract aphakia intraocular lens iol optical correction of aphakia
building employment skills through therapy for veterans

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: schizophrenia/schizoaffective disorder is associated with serious problems with cognitive skills, social skills, and functional skills (like employment). there is a new form of cognitive behavioral therapy called integrated cognitive behavioral therapy (icbt) that specifically addresses the cognitive, social, and functional deficits of schizophrenia/schizoaffective disorder. this study compared icbt to the usual care (uc) that veteran's receive. the investigators compared icbt to uc in subjects with schizophrenia/schizoaffective disorder who are enrolled in a supported employment (se) program, and evaluate whether icbt is more helpful in improving job attainment, and other areas of functioning, both right after treatment, and 6 months after the end of treatment.

the objective of the current study was to evaluate whether integrated cognitive behavior therapy (icbt) can improve engagement and success in an existing supported employment (se) program among the most functionally disabled patients with schizophrenia/schizoaffective disorder. the icbt condition also included computerized cognitive remediation. the primary specific aim was to determine whether icbt will significantly improve work outcomes at post-treatment to a greater extent than usual care (uc) in low functioning patients with schizophrenia/schizoaffective disorder who join the se program. the secondary aims were to evaluate the whether icbt will significantly improve work outcomes at 6 month follow-up relative to uc, and whether icbt will improve functional outcomes post-treatment and at follow-up relative to uc in subjects who join the se program.

Eligibility criteria:
inclusion criteria: * diagnosis of dsm-iv schizophrenia or schizoaffective disorder (scid) * severe/extreme functional disability \[world health organization disability assessment scale (whodas) score \> 50\] * clinical stability (as per primary mental health provider) * receiving treatment at the veterans administration * minimal engagement in psychiatric rehabilitation services (just psychiatrist and therapist/case management in the last 6 months) * eligible for and willing to be enrolled in supported employment program * age 18 to 65 * proficient in english * able to give informed consent exclusion criteria: * neurologic disease or damage that would make the diagnosis of schizophrenia questionable * current opioid or stimulant dependence (scid) * not appropriate due to safety concerns (based on risk assessment)

Keywords: schizophrenia cognitive behavioral therapy cognition vocational rehabilitation supported employment schizoaffective disorder
imaging silent brain infarct and thrombosis in acute myocardial infarction

Conditions: Myocardial Infarction; Acute Disease; Thrombosis; Heart Diseases; Stroke

Summary: this project aims to assess the ability of cardiac imaging (cardiac mri and doppler-echocardiography) post-processing tools to predict a combined end-point of intraventricular thrombosis, silent brain infarcts, clinical stroke and peripheral arterial embolism in patients with first acute myocardial infarction and ventricular dysfunction.

an acute myocardial infarction (ami) is a clinical situation that entails an increased risk of both subclinical and clinically devastating cardioembolic events. this increased risk of embolic phenomena may be related to blood stasis caused by alterations in the blood flow inside the left ventricle (lv) after ami. using flow velocity measurements obtained by cardiac mri and doppler-echocardiography it is possible to quantify the stasis in the lv and assess its relation to the risk of embolic events. the ability of cardiac imaging (cardiac mri and doppler-echocardiography) post-processing tools to predict embolic events in a cohort of 92 patients with a first ami and left ventricular dysfunction shall be addressed. the potential confusion generated by the possible existence of paroxysmal af will be controlled by implanting cardiac monitoring devices in random order in a subset of patients.

Eligibility criteria:
inclusion criteria: 1. first st elevation ami undergoing (or not) revascularization. 2. sinus rhythm in the first 24 hours of the ami. 3. written informed consent. ( 4) left ventricular ejection fraction \< 45% measured by echocardiography in the first 24-72 hours after ami symptoms onset. exclusion criteria: 1. implantable defibrillation or stimulation devices not compatible with mri. 2. killip-iv class or other shock situations or marked peripheral hypoperfusion. 3. aborted sudden death or other causes of possible acute brain damage attributed to cerebral hypoperfusion. 4. hemodynamically significant valvular disease or prosthetic heart valves. 5. claustrophobia that impedes mri scanning. 6. atrial fibrillation (af) in the first 24 hours after ami. 7. carotid artery disease diagnosed with stenosis greater than 50%. 8. full oral anticoagulation prior to admission or indication of anticoagulation. 9. defined pro-thrombotic conditions. 10. history of previous stroke in the last 6 months.

Keywords: acute myocardial infarction cardiac embolism intracardiac fluid dynamics silent brain infarct intracardiac blood stasis
electronic nose and fetal chromosomal disorders

Conditions: Detecting Abnormal Fetal Karyotype by the Electronic Nose

Summary: "electronic nose"- the tiny sensors, will smell and detect the changes in the sample of abnormal fetal karyotype, and fluid that will be confirmed by amniocentesis.

the biochemical engineering department had developed a device called "electronic nose" that can detect various diseases including cancer and asthma on basis of evaporable substances. the device simulates the human nose ", which includes an array of tiny sensors connected to nanometric sizes electronic calculating unit.. thanks to their small size, electrical, physical and chemical properties, the sensitive sensors smell and identified changes in composition of the materials that characterize various diseases including kidney disease and asthma. the electronic nose was developed by professor haick from the technion. the main concept of the device is testing and characterization a trace amounts of substances in the air with the help of nana-technology sensors the idea is revolutionary and would allow the diagnosis of different diseases, like cancer, by exhaling air into the device. the test is simple and not complicated to perform ,the examiner inhale air into a bag which connected to the "electronic nose". the molecules of the patient's breath will be tied to sensors and transmit an electrical signal to computer chip. after processing the data the "electronic nose "can distinguish between normal cells and pathological cells. hypothesis: the tiny sensors ("electronic nose") will smell and detect the changes in the sample of abnormal fetal karyotype, and fluid that will be confirmed by amniocentesis.

Eligibility criteria:
inclusion criteria: * pregnant women candidates for amniocentesis * 17-33 gestational weeks exclusion criteria: * women that refuse to participate in the research * women older than 45 or less than 16

Keywords: electronic nose abnormal fetal karyotype
18f-ln1 pet/ct in urothelial carcinomas

Conditions: Urothelial Carcinoma

Summary: the clinical feasibility of 18f-ln1 pet/ct will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18f-fdg.

this study aims to evaluate the recognition efficiency of 18f-ln1 and 18f-fdg pet imaging for tumor target nectin-4 in patients with urothelial carcinoma. the main method is to compare the results of visually interpreted pet images with histopathological results (through surgery or biopsy), which are the gold standard for final diagnosis.

Eligibility criteria:
inclusion criteria: * age 18 and above * no gender difference * patients who have been diagnosed with, or are clinically highly suspected of, urothelial carcinomas and have had no other treatment within 3 months exclusion criteria: * hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmhg * complicated with chronic liver disease, myocardial infarction, stroke * female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception * abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
effects of stellalife oral care recovery kit on palatal wound healing after free gingival graft

Conditions: Wound Heal

Summary: this study looks to compare the clinical effects of stellalife vega oral care kit with chlorhexidine mouth-rinse on patient comfort, wound healing, wound epithelialization, bacterial levels, and colonization of the wounds.

a total of 60 participants will be recruited from those needing and have been treatment planned for a free gingival graft surgery to increase keratinized gum. the study subjects will be randomly allocated to either negative control group (nc), chlorhexidine group (c) or stellalife group (s) by randomization done using a computer-generated table. the nc group is provided normal saline mouth-rinse to rinse 2 times per day along with placebo gel to be applied 2 times and placebo oral spray. the s group will use stellalife oral care mouth-rinse, gel and spray 2 times per day. the c group will use chlorhexidine mouth-rinse and placebo gel and spray 2 times per day. all groups beginning the same day and continuing for the duration of two weeks. all patients will receive a protective splint. following this, subjective and objective measurements on the success of the mouthwash and oral care kit will be measured. patients will be evaluated post operatively following surgery as mentioned below: * wound healing assessment and epithelization assessment: postoperative days 1, 5, 14, 21 and 28 * oral health impact profile-14 and functional pain scale: starting on the day of the surgery and postoperative days 1, 5, 14, 21 and 28 * wound exudate assessment: samples collected on postoperative days 1, 5, 14, 21 and 28 * wound plaque assessment: starting on the day of the surgery and postoperative days 1, 5, 14, 21 and 28

Eligibility criteria:
inclusion criteria: * adults aged ≥18 years, * no history of medication affecting periodontal status in the last 6 months, * no history of allergy to study medication or material, * no use of tobacco, * no history of pregnancy or lactation or contraceptive medication * good oral hygiene. exclusion criteria: * previous palatal surgery * patient on anticoagulant therapy * uncontrolled diabetes, * rheumatoid arthritis, * osteoporosis.

Keywords: inadequate keratinized gingiva mouthrinse
impact of supplemental parenteral nutrition in icu patients on metabolic, inflammatory and immune responses

Conditions: Critical Illness

Summary: having previously demonstrated that supplemental parenteral nutrition to complete an insufficient enteral nutrition (en) between d4 and d8 improves outcome after critical illness, by reducing infectious complications, the present trial aims at investigating the underlying carbohydrate and protein metabolism changes, as well as the immune and inflammatory modulations associated with this improvement.

enrollment on day 3 of critically ill patients, without contraindication to en, not achieving 60% of the icu per protocol energy target. intervention: randomization to either continued pure en, or from day 4 to supplemental pn to complete en at target validated by indirect calorimetry. measurements: indirect calorimetry on days 3, 4, 9 (twice). primary endpoints = glucose and leucine metabolism on days 4 and 9-10: isotopic investigation of glucose metabolism, and immune and inflammatory responses// day 9-10: isotopic investigation of protein (leucine) metabolism secondary endpoints: insulin requirements, area under the curve (auc) of blood glucose, infections after day 9, overall complications, length of mechanical ventilation, of icu and hospital stay.

Eligibility criteria:
inclusion criteria: * estimated duration of icu stay \> 5 days, * estimated survival \> 7 days, * absence of contraindication to en * need for mechanical ventilation * informed consent obtained from patients, close relative, or referring physician exclusion criteria: * refusal of the patient or of the next of kin * age \< 18 years * non-functional digestive tract (short bowel, persistent ileus, proximal intestinal fistula high rate \> 1.5 litres/day) * already receiving pn before day 3 * absence of a central venous catheter * women who are pregnant (pregnancy test). * admission after cardiac arrest, or severe brain injury

Keywords: energy requirements, glucose turnover, protein turnover
the ritai cohort: an observational study on rituximab off-label use for auto-immune disorders

Conditions: Pemphigus; Auto-immune Thrombocytopenic Purpura; Hemolytic Auto-immune Anaemia; Cold Agglutinin Disease; Cryoglobulinemia

Summary: the primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.

every patient treated by rituximab off -label for auto-immune diseases in the public hospitals of the midi-pyrénées county (france) is eligible for the study, whatever the dose and the number of planned infusions. the enrollment is definitive at the time the first rituximab infusion begins. follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. at each visit, the investigators will record the adverse events that have occurred since the last visit. serious or unexpected adverse events will be systematically monitored and declared to the pharmacovigilance. imputability will be quoted according to the french method. a biological collection will be constituted to allow pharmaco- immunological studies.

Eligibility criteria:
inclusion criteria: * age over 18 years * rituximab is prescribed off-label for an auto-immune disorder * rituximab prescription is validated by an institutional board * patients have given their informed consent to be included in the cohort exclusion criteria: * follow-up for 6 months presumably doubtful * rituximab is prescribed for rheumatoïd arthritis * rituximab is prescribed for lymphoma * pregnant or breath feeding women

Keywords: observational cohort rituximab off-label use auto-immunity cytopenia
endothelial function and circulating microparticle in patients under lvad support

Conditions: End Stage Heart Failure

Summary: the aims of this project are 1) to evaluate whether circulating micraparticals (mps) in patients with lvad impair endothelial function and 2) to assess the procoagulative activity of circulating mps in patients with lvad in a prospective longitudinal study of patients undergoing lvad implantation, 3) to analyze these parameters in the context of thromboembolic events.

continuous-flow left ventricular assist devices (lvads) have arised as a vital therapeutic option in end stage heart failure not merely as bridge-to transplant but also as destination therapy. lvads are associated with impaired endothelial function as well as with a dysbalance of coagulation leading to both, excessive bleeding and thromboembolic events, respectively. microparticles (mps) are shed membrane particles budded into the circulation and considered as a marker of compromised endothelial integrity and enhanced procoagulation levels. in addition, mps have been suggested to play an active role in the induction of endothelial dysfunction and coagulation. first studies demonstrated increased level of mps in patients with lvad. whether circulating mps contribute to impaired endothelial function and enhanced coagulation in patients with lvad and thereby promote thrombotic complications is unknown. the aims of this project are 1) to evaluate whether circulating mps in patients with lvad impair endothelial function and 2) to assess the procoagulative activity of circulating mps in patients with lvad in a prospective longitudinal study of patients undergoing lvad implantation, 3) to analyze these parameters in the context of thromboembolic events.

Eligibility criteria:
inclusion criteria: * inclusion criteria: chronic heart failure intermasc 5-7 or * patients on lvad support exclusion criteria: * current thrombembolic or bleeding event

Keywords: circulating mp fmd lvad endothelial function endothelial integrity
gene expression profiling in subjects with postoperative atrial fibrillation after cardiac surgery (genexpro surg)

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is a type of irregular heartbeat that is common after having heart surgery. there may be many different reasons why some people get atrial fibrillation after their heart surgery. these reasons may include that a person is older or that he/she is taking certain types of medications before surgery. genes may also be a reason. genes contain the material passed from parent to child that determines the make-up of the body and mind. for example, some genes control the color of your hair or eyes. some people may have genes that make it more likely for them to get atrial fibrillation after their heart surgery. this research project is being done to find out if the cells of people who develop atrial fibrillation after heart surgery are different from the cells in people who do not develop atrial fibrillation after surgery.

atrial fibrillation is a type of irregular heartbeat that is common after having heart surgery. there may be many different reasons why some people get atrial fibrillation after their heart surgery. these reasons may include that a person is older or that he/she is taking certain types of medications before surgery. genes may also be a reason. genes contain the material passed from parent to child that determines the make-up of the body and mind. for example, some genes control the color of your hair or eyes. some people may have genes that make it more likely for them to get atrial fibrillation after their heart surgery. this research project is being done to find out if the cells of people who develop atrial fibrillation after heart surgery are different from the cells in people who do not develop atrial fibrillation after surgery. this study seeks to identify regulatory events in atrial myocyte transcription and translation that are altered by germline variation

Eligibility criteria:
inclusion criteria: * age 20-99 years * undergoing cardiac surgery exclusion criteria: * prior cardiac surgery * chest radiation * recent chemotherapy

Keywords: atrial fibrillation gene expression genetic